The bulky N(6) substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine (5-HT)2Aand 5-HT2B receptors and thus is a determinant of valvular heart disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 381-391

  Kekewska, Alexandra ^a   Hübner, Harald ^b   Gmeiner, Peter ^b   Pertz, Heinz H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLCABERGOLINE; CABERGOLINE; COLLAGEN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCOSAMINOGLYCAN; KETANSERIN; MITOGEN ACTIVATED PROTEIN KINASE 1; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; UNCLASSIFIED DRUG; VOLINANSERIN; ERGOLINE DERIVATIVE; SEROTONIN AGONIST;

ANIMAL CELL; ANIMAL TISSUE; AORTA VALVE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FEMALE; LEYDIG CELL; LUNG ARTERY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VALVULAR HEART DISEASE; VASODILATATION; ANIMAL; CELL CULTURE; CHEMISTRY; CHO CELL; COMPARATIVE STUDY; CRICETULUS; DRUG EFFECT; HAMSTER; HUMAN; METABOLISM; PULMONARY ARTERY; SWINE;

ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; ERGOLINES; HEART VALVE DISEASES; HUMANS; PULMONARY ARTERY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN RECEPTOR AGONISTS; SWINE;

EID: 79959518063     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.181255     Document Type: Article

References (39)

1. Antonini A and Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 6:826-829. (Pubitemid 47243713)
2. Barzilla JE, Acevedo FE, and Grande-Allen KJ (2010) Organ culture as a tool to identify early mechanisms of serotonergic valve disease. J Heart Valve Dis 19:626-635.
3. Battaglia R, Strolin Benedetti M, Mantegani S, Castelli MG, Cocchiara G, and Dostert P (1993) Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man. Xenobiotica 23:1377-1389. (Pubitemid 24036135)
4. Bhattacharyya S, Schapira AH, Mikhailidis DP, and Davar J (2009) Drug-induced fibrotic valvular heart disease. Lancet 374:577-585.
5. Chester AH, Misfeld M, Sievers HH, and Yacoub MH (2001) Influence of 5-hydroxytryptamine on aortic valve competence in vitro. J Heart Valve Dis 10:822-825; discussion 825-826.
6. Chester AH, Misfeld M, and Yacoub MH (2000) Receptor-mediated contraction of aortic valve leaflets. J Heart Valve Dis 9:250-254; discussion 254-255.
7. Chester AH and Taylor PM (2007) Molecular and functional characteristics of heartvalve interstitial cells. Phil Trans R Soc B 362:1437-1443. (Pubitemid 47201768)
8. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, and Lombardi G (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777-3784.
9. Connolly JM, Bakay MA, Fulmer JT, Gorman RC, Gorman JH 3rd, Oyama MA, and Levy RJ (2009) Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. Am J Pathol 175:988-997.
10. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81.
11. Glusa E and Pertz HH (2000) Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors. Br J Pharmacol 130:692-698. (Pubitemid 30332990)
12. Görnemann T, Hübner H, Gmeiner P, Horowski R, Latté KP, Flieger M, and Pertz HH (2008) Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine2B and 5-hydroxytryptamine2A receptors. J Pharmacol Exp Ther 324:1136-1145. (Pubitemid 351397829)
13. B subtypes in a heterologous cell line. Mol Endocrinol 6:920-926.
14. 2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 29:80-86.
15. Hoyer D and Boddeke HW (1993) Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14:270-275. (Pubitemid 23204245)
16. 2B receptor agonists: implications for drug safety assessment. Mol Pharmacol 76:710-722.
17. 1B receptor ligands. Bioorg Med Chem Lett 15:4786-4789.
18. 3 subtype. J Med Chem 43:756-762.
19. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, and Levy RJ (2002) Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-β1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 161:2111-2121. (Pubitemid 35434857)
20. Kars M, Pereira AM, Bax JJ, and Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159:363-367.
21. Kenakin TP (1993) Pharmacological Analysis of Drug-Receptor Interaction, 2nd ed, Raven Press, New York.
22. Kershaw JD, Misfeld M, Sievers HH, Yacoub MH, and Chester AH (2004) Specific regional and directional contractile responses of aortic cusp tissue. J Heart Valve Dis 13:798-803.
23. 2B receptors. Naunyn-Schmiedebergs Arch Pharmacol 379:461-471.
24. Maddahi A and Edvinsson L (2008) Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway. BMC Neurosci 9:85.
25. Marano M and Kaumann AJ (1976) On the statistics of drug-receptor constants for partial agonists. J Pharmacol Exp Ther 198:518-525.
26. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, et al. (2006) Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113:81-89. (Pubitemid 43958492)
27. 1 like receptors. Cardiovasc Drugs Ther 4:1455-1460.
28. 2-adrenoceptor. J Pharmacol Exp Ther 303:805-814.
29. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, and Millan MJ (2002b) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1, and 5-HT2, receptor subtypes. J Pharmacol Exp Ther 303:815-822. (Pubitemid 35231258)
30. Oertel WH, Trenkwalder C, Zucconi M, Benes H, Borreguero DG, Bassetti C, Partinen M, Ferini-Strambi L, and Stiasny-Kolster K (2007) State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 22 (Suppl 18):S466-S475.
31. Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6-9.
32. Roy A, Brand NJ, and Yacoub MH (2000) Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis 9:256-260; discussion 260-261.
33. Schoen FJ (2005) Cardiac valves and valvular pathology: update on function, disease, repair, and replacement. Cardiovasc Pathol 14:189-194.
34. Schlotter K, Boeckler F, Hübner H, and Gmeiner P (2005) Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles. J Med Chem 48:3696-3699. (Pubitemid 40776844)
35. Serratrice J, Disdier P, Habib G, Viallet F, and Weiller PJ (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334-336. (Pubitemid 35266254)
36. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, and Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229. (Pubitemid 36627216)
37. Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P, et al. (2010) Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 73:369-374.
38. 2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 161:2209-2218.
39. Xu S and Grande-Allen KJ (2010) The role of cell biology and leaflet remodeling in the progression of heart valve disease. Methodist Debakey Cardiovasc J 6:2-7.